PMC51 CONCEPT ELABORATION—AN ESSENTIAL STAGE IN THE TRANSLATION OF PRO MEASURES  by Verjee-Lorenz, A et al.
A338 13th Euro Abstracts
PMC49
THE ROLE OF PATIENT-REPORTED OUTCOMES (PRO) AS PRIMARY 
ENDPOINTS IN THE EVALUATION OF MEDICINES APPROVED WITH 
PRO CLAIMS
Caron M, Emery MP
MAPI Research Trust, Lyon, France
OBJECTIVES: To review the drugs that used PRO as primary endpoints in the evalu-
ation of their clinical efﬁ cacy and have been granted a PRO claim by the Food & 
Drug Administration (FDA) or the European Medicines Agency (EMA). METHODS: 
The PROLabels database, which centralizes medicinal products with a PRO claim, 
was searched using the keyword “primary endpoint”. Only drugs approved between 
January 1, 1995 and May 28, 2010 were included. RESULTS: A total of 303 (66%) 
out of the 459 products included in the database were retrieved: four were removed 
because of a withdrawal notice (all EMA), 15 because they were approved before 
1995, and two others because the endpoints were not clearly speciﬁ ed. In total, 282 
products were analyzed (71 approved in Europe). They represented 81 different indica-
tions, with 47 products having more than one indication. The most frequent indica-
tions were: Pain (25 products), Rheumatoid Arthritis (25), Menopause (18), 
Parkinson’s disease (17), Epilepsy (15), Migraine disorders (13), Sleep disorders (12), 
Rhinitis Allergic Perennial, Seasonal (12), and Ankylosing Spondylitis (10). In total, 
140 different PRO endpoints were listed. Seventy-seven percent of them were symp-
toms (e.g. pain, bowel movement, heartburn symptoms, asthma symptoms, etc). 
Function (e.g. physical function, functional impairment, etc) represented only 5.7% 
of all endpoints. Health-related quality of life (HRQL) was a clear primary endpoint 
in only two products: Duloxetine (Urinary Incontinence) and Alisade (Rhinitis Allergic 
Perennial and Seasonal). Both approvals were granted by the EMA in 2008 (after the 
ﬁ rst publication of the EMA and FDA guidances). CONCLUSIONS: Symptoms, as 
measured by patients, are a key criterion in the evaluation of medicines. Unsurpris-
ingly, pain is the main indication in which the highest number of products with a PRO 
as a primary endpoint are approved. More sophisticated PRO endpoints, such as 
function or HRQL, are used less often.
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TRANSLATION, LINGUISTIC VALIDATION AND ELECTRONIC 
ADMINISTRATION IN THE INDIAN LANGUAGES: A CASE STUDY 
HIGHLIGHTING THE SPECIAL DIFFICULTIES THAT EXIST AT THIS 
INTERSECTION
Handa M1, Brandt B2, Hasegawa N1, McKown S1, Gawlicki M2
1Corporate Translations, Inc, Chicago, IL, USA; 2Corporate Translations, Inc, East Hartford, 
CT, USA
OBJECTIVES: Translation and linguistic validation of questionnaires for paper or 
electronic administration require similar procedures. Both modalities share a common 
difﬁ culty: how to best utilize existing processes to accommodate Indian languages. 
Working with Indian language instruments can be daunting, even without the com-
pounded effect of managing both ePRO and linguistic validation together. This paper 
seeks to enumerate the challenges associated with the intersection of Indian languages, 
linguistic validation, and electronic administration and recommends the use of a 
specialized checklist to avoid escalating potential difﬁ culties. METHODS: A case 
study was performed to explore the complexity of these processes. a Fibromyalgia 
e-diary and corresponding paper diary were translated into four Indian languages and 
three non-Indian languages with varying levels of linguistic difﬁ culty. This allowed for 
a multidimensional analysis of issues faced in translation for ePRO versus paper 
administration, and translation for Indian versus non-Indian settings. RESULTS: 
During linguistic validation, difﬁ culties arise pertaining to font and formatting require-
ments, localization of colloquial terms and phrases and maintaining concept equiva-
lency while respecting cultural appropriateness. Preparing an ePRO for use involves 
thorough analysis of existing instrument versions and possible modiﬁ cation of instruc-
tions, response sets or questionnaire format to accommodate technology or screen size 
limitations. a holistic approach of quality assurance should be employed, including 
multiple rounds of proofreading. When preparing an Indian language for electronic 
administration one must take even more care, accounting for the factors listed above 
as well as considering software font-testing prior to production, and additional proof-
reading steps. CONCLUSIONS: Linguistic validation of ePRO questionnaires for use 
in Indian settings presents special challenges. Evidence suggests that additional con-
sideration must be exercised early on in order to avoid compounded difﬁ culties and 
delays later in the process. In such cases, the use of a checklist is recommended to 
assist in preempting future difﬁ culties within the project.
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CONCEPT ELABORATION—AN ESSENTIAL STAGE IN THE 
TRANSLATION OF PRO MEASURES
Verjee-Lorenz A, Clayson D, Two R, Giovanaz M
PharmaQuest Ltd, Banbury, Oxfordshire, UK
The ISPOR Principles of Good Practice paper for the translation of patient-reported 
outcome (PRO) measures describes concept elaboration within the scope of project 
preparation and emphasises that the misinterpretation of items or concepts can result 
if the step is not undertaken. However, the paper does not discuss how to correctly 
perform concept elaboration or why it is an essential step in the translation process. 
Translation companies often harmonise their own translations with each other, but 
not with existing translations. Over time, a single measure may be translated by any 
number of companies. Wording choices are often made by various translators and 
project managers without prior guidance—this can lead to wide variations. a concept 
elaboration document approved by the developer provides consistent clariﬁ cation and 
guidance to promote harmonization across all language versions regardless of who is 
carrying out the work. Inconsistent wording choices across language versions can be 
due to misunderstandings as a result of ambiguous wording in the source text, misin-
terpretation of idioms or the inﬂ uence of personal choice resulting in inconsistent use 
of alternative phrases for terms that are not directly translatable. Concept elaboration 
remedies these issues by providing a line-by-line analysis of the source text which 
clariﬁ es ambiguous wording, provides alternative wording for items with no direct 
translation, recommends suitable equivalents of culture-bound concepts and provides 
guidelines on nuance, tone, and emphasis. Concept elaboration ensures that the text 
is fully understood by all translators before any translation work begins. It encourages 
standardised decision making for every language and allows the developer to exercise 
inﬂ uence over the style and content of the translations even if they are unable to review 
each translation individually. For studies including developer reviews, these reviews 
should become more straightforward as the translations will have been carried out 
according to the developer’s guidance.
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TREATMENT SATISFACTION WITH MEDICATION: A REVIEW OF 
CONCEPTUAL FRAMEWORKS AND APPLICATIONS
Bharmal M, Viswanathan S
Quintiles, Rockville, MD, USA
OBJECTIVES: The construct of treatment satisfaction with medication (TS-M) pro-
vides an avenue for incorporating the patients’ voice in treatment evaluation. In recent 
years, due to the growing inﬂ uence of the consumer in health care decisions, there 
have been a substantial number of both generic and disease-speciﬁ c TS-M instruments 
developed. This study provides a review of the available TS-M measures and examples 
of its applications. METHODS: A literature review was conducted using MEDLINE, 
ISPOR Research Digest and Google Scholar to identify generic and disease-speciﬁ c 
TS-M instruments as well as any applications of these instruments. The review 
included evaluation of research articles, abstracts, review articles, news articles and 
editorials discussing instruments that measure TS-M. RESULTS: A total of 39 instru-
ments that measure TS-M were identiﬁ ed. Out of the 39 instruments, four instruments 
were generic in nature that could be used across therapy areas and included the three 
versions of the Treatment Satisfaction Questionnaire for Medication (TSQM) (TSQM 
v1.4, TSQM vII, TSQM-9) and the SATMED-Q. The rest of the 35 measures were 
disease-speciﬁ c TS-M instruments covering many diseases including migraine, pain, 
HIV, diabetes, Crohn’s disease, oncology, osteoarthritis, men’s health and multiple 
sclerosis. The instruments varied substantially in the number of items and domains 
they covered and included anywhere from 6 items to 46 items. Treatment satisfaction 
data has been used to inform clinician decision-making, support label claims, and for 
supporting the marketing of drugs. For example, in the past decade, TS-M has been 
used to support label claims for 17 products in Europe and in marketing effort of 
drugs in many therapy areas including erectile dysfunction, heart disease and diabetes. 
CONCLUSIONS: Treatment satisfaction with medication can be an important end-
point for product differentiation of novel treatments. Among the existing TS-M 
instruments, researchers could beneﬁ t by identifying instruments that have been devel-
oped using psychometrically rigorous standards and procedures.
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COMPARISON OF METHODS FOR ITEM GENERATION AND 
PRETESTING OF FIVE LYMPHOEDEMA-SPECIFIC HEALTH-RELATED 
QUALITY OF LIFE QUESTIONNAIRES
Williams AE
Biomarin Europe Ltd, London, UK
OBJECTIVES: A systematic literature review identiﬁ ed four patient-reported outcome 
(PRO) measures that have been used in the assessment of quality of life for patients 
with upper limb lymphoedema. These are in addition to the author’s newly devised 
questionnaire. However the developers had all used different methods to devise the 
items with the ﬁ nal measures incorporating different items and domains. The objective 
was to compare the methods that had been used and review in the light of available 
guidance on best practice. METHODS: Review and tabulate the available information 
on each PRO regarding its development. Key aspects of the evaluation included speci-
ﬁ city of target population, source of item generation, number of initial items gener-
ated, drafting of item/question wording, pretesting and deﬁ ning the domains. 
RESULTS: Two of the ﬁ ve PROs had been developed to assess the quality of life of 
patients with upper or lower limb lymphoedema decreasing the speciﬁ city of the target 
population; two of the PROs did not use patients as the source for items relying on 
clinicians; the number of items initially generated by the remaining three PROs were 
98, 134 and 495, but none of the developers evaluated the point of saturation; differ-
ent approaches were used for analyses of the items generated to create the initial draft 
of items/questions; not all PROs were pretested. Number of domains ranged from two 
to seven and number of items/questions in initial drafts ranged from 5 to 70. CON-
CLUSIONS: Each of the PROs measuring the same concept have been developed using 
different methods of generating the items and pretesting an initial draft of the PRO. 
To advance the ﬁ eld of measuring quality of life of lymphoedema patients, it will be 
important to establish which PRO measure has the best validity, that is, best reﬂ ects 
the impact of lymphoedema on their health and well-being.
